DR. REDDY'S LABORATORIES-ADR (RDY)
US2561352038 - ADR
Dr. Reddy’s Q2 & H1FY25 Financial Results
Get insights into the top gainers and losers of Tuesday's pre-market session.
Top movers in Tuesday's pre-market session
RDY Crosses Below Key Moving Average Level
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
Dr. Reddy’s Q1FY25 Financial Results
Dr. Reddy's Labs Stock Sees Improved Technical Strength
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.
RDY Crosses Below Key Moving Average Level
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
RDY Crosses Below Key Moving Average Level
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
Novo to face Wegovy rivalry in India as local versions loom
Novo Nordisk (NVO) faces scrutiny as Indian drugmakers develop their versions of its weight loss therapy Wegovy. Read more here.
Dr. Reddy’s Q3 & 9M FY24 Financial Results
Journey Medical submits NDA for DFD-29 for rosacea (NASDAQ:DERM)
Journey Medical (FBIO) said it has submitted a New Drug Application for its rosacea treatment DFD-29. The product is being developed with Dr. Reddy's (RDY). Read more here.
Dr. Reddy's acquires MenoLabs business from Amyris (NYSE:RDY)
Dr. Reddy's Laboratories has announced the acquisition of Amyris' women's health and dietary supplements portfolio.
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
Dr. Reddy's acquires 6.46% stake in Israeli biotech Edity Therapeutics (NYSE:RDY)
Dr. Reddy's Laboratories (RDY) has acquired a 6.46% stake in Edity Therapeutics, an Israeli biotech focused on using immune cells to deliver therapeutics proteins. Read more here.